Greenwich Rx recall names 10 compounded glutathione lots over potential endotoxin risk
October 1 recall notice: 10 lots named for potential elevated endotoxin levels. Scope and evidence limits matter.
Greenwich Rx announced a nationwide voluntary recall of 10 lots of compounded glutathione injection on October 1 because of potential elevated endotoxin levels. FDA posted the company's announcement the same day. This is a dated recall notice, not a new FDA finding issued today.
The company said the recalled product was distributed to patients nationwide between June 26 and September 21, 2026. Its announcement reports two patients received emergency department care after intravenous administration of a glutathione product that was not formulated for intravenous use. The notice does not establish that all glutathione products have the same risk or that endotoxin caused those two events.
The listed lots are 0060-062426-1, 0060-062726-1, 0060-070926-1, 0060-071426-1, 0060-071426-2, 0060-072026-1, 0060-072726-1, 0060-072926-1, 0060-073126-1 and 0060-080426-1. The FDA-hosted announcement includes each lot's beyond-use date and product-label image for identification.
The notice says elevated endotoxin levels in injectable products can cause serious events, including fever, low blood pressure, inflammatory reactions, anaphylactic shock and death. Those are the notice's risk warnings, not a statement that every recalled vial produced those effects.
What readers can check: compare the exact lot identifier against the original recall notice. The company's announcement tells customers with a recalled lot to stop using it and follow disposal instructions in their recall notification. It tells patients with a suspected related health issue to contact their healthcare provider. No dose or injection guidance is supplied here.
Limits: FDA hosts this company announcement as a public service and does not endorse the company or product. The page remains accessible on October 8; that alone does not establish recall completion status. This brief does not cover every compounded glutathione product and is not a treatment recommendation.